CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure

Haematologica

Volumn 94, Issue 3, 2009, Pages 423-427

  Johnson, Nathalie A ^a   Leach, Stephen ^b   Woolcock, Bruce ^a   Deleeuw, Ronald J ^c   Bashashati, Ali ^c   Sehn, Laurie H ^d   Connors, Joseph M ^d   Chhanabhai, Mukesh ^a   Brooks Wilson, Angela ^b   Gascoyne, Randy D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b CANADA'S MICHAEL SMITH GENOME SCIENCES CENTRE   (Canada)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

CD20 antigen; DLBCL; Mutation; R CHOP

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; RITUXIMAB; VINCRISTINE;

ARTICLE; DRUG PROTEIN BINDING; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BINDING SITES, ANTIBODY; CYCLOPHOSPHAMIDE; DNA MUTATIONAL ANALYSIS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPITOPES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; VINCRISTINE;

EID: 62949152339     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.001024     Document Type: Article

References (24)

1. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-66.
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CflOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
3. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-33.
4. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-7.
5. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood 2006; 108:1975-8.
6. Du J, Wang H, Zhong C, Peng B, Zhang M, Li B, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem 2007;282:15073-80.
7. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68.
8. Jaffe ES, Harris NL, Stein H, Vardiman JW. World health organization classification of tumours, pathology & genetics: tumours of haematopoietic and lymphoid tissues: IARC Press: Lyon, France. 2001.
9. Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004;41:508-17.
10. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence- based resequencing. Nucleic Acids Res 1997;25:2745-51.
11. Gordon D, Abajian C Green P. Consed: a graphical tool for sequence finishing. Genome Res 1998;8:195-202.
12. Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, van Dongen JJ. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990;136:1215-22.
13. Ishii Y, Takami T, Yuasa H, Takei T, Kikuchi K. Two distinct antigen systems in human B lymphocytes: identification of cell surface and intracellular antigens using monoclonal antibodies. Clin Exp Immunol 1984;58: 183-92.
14. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttran-scriptional levels. Clin Cancer Res 2008;14:1561-70.
15. Terui Y, Mishima Y, Yokoyama M, Mishima Y, Takeuchi K, Ito Y, et al. Use of C-terminal deletion mutation of CD20 molecule to predict CD20 expression and time to progression after rituximab in non-Hodgkin lymphoma. J Clin Oncol 2007;ASCO Annual Meeting Proceedings Part I.
16. Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998;273:344-8.
17. Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 1998; 161:3242-8.
18. Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DC, Vandlen RL. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005;44:15150-8.
19. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-5.
20. Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, et al. Incidence and nature of CD20-nega-tive relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol 2002;119: 412-6.
21. Haidar JH, Shamseddine A, Salem Z, Mrad YA, Nasr MR, Zaatari G, et al. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol 2003;70:330-2.
22. Seliem RM, Freeman JK, Steingart RH, Hasserjian RP. Immunophe-notypic changes and clinical outcome in B-cell lymphomas treated with rituximab. Appl Immunohistochem Mol Morphol 2006;14:18-23.
23. Serke S, Schwaner I, Yordanova M, Szczepek A, Huhn D. Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses. Cytometry 2001; 46:98-104.
24. Chen W, Houldsworth J, Olshen AB, Nanjangud G, Chaganti S, Venka-traman ES, et al. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood 2006;107: 2477-85.